Interval dosing with the HDAC inhibitor vorinostat effectively reverses HIV latency

Abstract excerpt

BACKGROUND: The histone deacetylase (HDAC) inhibitor vorinostat (VOR) can increase HIV RNA expression in vivo within resting CD4+ T cells of aviremic HIV+ individuals. However, while studies of VOR or other HDAC inhibitors have reported reversal of latency, none has demonstrated clearance of latent infection. We sought to identify the optimal dosing of VOR for effective serial reversal of HIV latency. METHODS: In...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Histone Deacetylase Inhibitors Research
• Share to HIV/AIDS drug development and treatment
• Share to HIV Research and Treatment